Skip to main content
. Author manuscript; available in PMC: 2020 Oct 11.
Published in final edited form as: Circ Res. 2019 Oct 10;125(9):855–867. doi: 10.1161/CIRCRESAHA.119.315378

Figure 2.

Figure 2

hiPSC-CMs assay can replicate the HCV-NS5B NI/Amiodarone cardiac DDIs observed in clinic and preclinical models, provide a competitive advantage for early screening/de-risking of new HCV-NI candidates, and rapidly assess the putative mechanism(s) responsible of DDIs.